Please ensure Javascript is enabled for purposes of website accessibility

Why ImmunoGen Stock Is Flying High Today

By George Budwell – Dec 1, 2021 at 8:25AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is continuing to surge after after a late-stage win in treatment for advanced ovarian cancer.

What happened

Shares of ImmunoGen (IMGN 1.61%), a small-cap specialist in antibody-drug conjugates (ADCs), were up a healthy 13.1% as of 12:17 p.m. ET Wednesday. The biotech's shares are extending yesterday's rally following a positive top-line data readout for mirvetuximab as a treatment for platinum-resistant ovarian cancer.  

What's noteworthy is that ImmunoGen's shares are up by double digits today despite a $175 million public offering announced after the closing bell Monday. That's a surefire sign that Mr. Market is indeed impressed with mirvetuximab's late-stage data.

An ovarian cancer sitting on a park bench.

Image source: Getty Images.

So what

ImmunoGen plans to seek approval from the Food and Drug Administration (FDA) for mirvetuximab in the first quarter of 2022, even though confirmatory data from a second trial isn't due out until late next year. The drugmaker's decision to move forward with a regulatory filing is based on the fact that mirvetuximab achieved a 32% objective response rate in this patient population.

The drug was also reportedly well tolerated in this study, with only 7% of patients dropping out of the trial. What's important to understand is that the current treatment options for advanced ovarian cancer have response rates in the low single digits and tend to come with significant toxicities.

Mirvetuximab, therefore, could be a major improvement in the standard of care for this patient population.  

Now what

Is ImmunoGen stock still worth buying after its two-day rally? The biotech's market cap presently stands at approximately $1.4 billion. Mirvetuximab, if approved, is forecast to generate around $400 million in sales for this indication by 2026. As biotechs with newly approved oncology drugs tend to trade at between three to five times peak sales from a historical standpoint, ImmunoGen's shares appear to be fairly valued at this point. Mirvetuximab, after all, still has to get the green light from the FDA. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.